Search results
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 16 hours agoProgression-free survival is how long patients live before their cancer worsens. The company added...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
The Joplin Globe· 21 hours ago(NYSE Amer.: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have ...
FDA greenlights CEL-SCI confirmatory study for Multikine By Investing.com
Investing.com· 7 days agoCEL-SCI Corporation (NYSE American: CVM) announced today that the U.S. Food and Drug Administration...
Square: Restaurant Worker Pay Jumps 66% in 7 Years
PYMNTS.com· 16 hours agoLabor costs continue to weigh on restaurants, according to a new report by Square. The point-of-sale payments company’s Quarterly Restaurant Report,...
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 5 days agoREDWOOD CITY, Calif. & SANTA MONICA, Calif. - Kite, a GileadCompany (NASDAQ: GILD), and Arcellx,...
The 3 Best Bargain Stocks to Buy in May 2024
InvestorPlace· 6 days agoThere are several types of bargain stocks available to buy in the stock market. There are, of course, traditional bargain stocks with very low valuations...
The Ultimate Ranking Of Canned Roast Beef, According To Customer Reviews
Daily Meal via Yahoo News· 3 days agoFrom pot pie to beef stew, roast beef does it all! But canned roast beef can sometimes be a bit...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 5 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel ...
Revolutionary mRNA Cancer Vaccine Shows Immense Promise in First-Ever Human Clinical Trial
SciTechDaily· 5 days agoIn a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine created at the...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
WRBL Columbus· 1 day agoDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2024 and provided a business update. "We are pleased that the feedback from the U.S.